GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress

• Galderma, the pure-play dermatology class chief with a 40+ yr heritage in dermatology, will current one oral, six symposia and 4 hub classes demonstrating its scientific experience and ongoing dedication to advancing dermatology
• 18 scientific and medical posters will unveil new knowledge on pores and skin illness consciousness and scientific innovation in prurigo nodularis, delicate pores and skin, zits, rosacea, non-melanoma pores and skin most cancers and onychomycosis

Galderma has introduced it is going to be showcasing its newest scientific updates at the 31^st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022. These embrace on-site medical knowledge shows, a symposia sequence and sales space actions, all specializing in serving sufferers by offering choices throughout the Therapeutic Dermatology, Dermo-cosmetics and Injectable Aesthetics classes. As the pure-play dermatology chief, Galderma’s vital presence at EADV reaffirms its dedication to delivering a really progressive, science-based portfolio of premium cutting-edge manufacturers and providers.

The newest science offered by Galderma at EADV displays the corporate’s vital investments in analysis and improvement with giant trials throughout a number of indications for extreme situations resembling prurigo nodularis, atopic dermatitis, zits, rosacea, non-melanoma pores and skin most cancers and onychomycosis. For over 40 years, Galderma has solely centered on dermatology and has confirmed to be one of many few gamers able to offering not solely best-in-class product options but in addition first-in-class options with new progressive modes of motion. Today, Galderma is a number one scientific voice in these illness areas and stays dedicated to delivering additional advances for sufferers with these and different extreme pores and skin considerations.

One of essentially the most awaited updates from the corporate this yr will likely be a give attention to IL-31, a neuroimmune cytokine that has been demonstrated to be a central mediator in prurigo nodularis and atopic dermatitis. The cytokine acts as a bridge between the immune and nervous programs and performs an important position in igniting and fueling the pathophysiological facets, together with itch and irritation^1,2. Two symposia and eight scientific posters will look at the illness burden, the position of IL-31 in these inflammatory pores and skin situations and coverings beneath improvement.

Another space of focus for Galderma will likely be on delicate pores and skin, which impacts a significant portion of the inhabitants with over 70% of ladies reporting affected by its results³. With its sturdy client pores and skin vary devoted to delicate pores and skin together with Cetaphil and the latest acquisition of Alastin Skincare, Galderma understands the necessity for particularly designed therapies and personalised skincare regimes. At the EADV this yr, Galderma, together with key opinion leaders, will likely be difficult the prevailing paradigms on delicate pores and skin and difficult the neighborhood on whether or not it ought to be thought of as a standalone pores and skin situation.

Other pores and skin situations that drive sufferers to their dermatologist are zits, rosacea, actinic keratosis and non-melanoma pores and skin most cancers, situations that have an effect on a major cross-section of society. Galderma has been researching these situations and bringing progressive merchandise to sufferers and shoppers for many years. At EADV, the corporate will current new knowledge and host scientific conferences and discussions to look at novel patient-centered, holistic approaches in every of those areas to help the identification of the most effective personalised therapy regimens for every affected person.

Galderma’s vital presence at EADV this yr displays its experience throughout these widespread and sometimes extreme pores and skin situations and is testomony to its dedication to advancing dermatology for each pores and skin story.

Below is a full checklist of actions happening.

Prurigo nodularis and atopic dermatitis

• Thinking otherwise about atopic dermatitis: It’s time for a brand new perspective – September 9, 1:00 PM – 2:00 PM CEST (Room: AMBER 3 and 4). Chaired by Professor Diamant Thaçi (Germany) and that includes Professor Marjolein de Bruin-Weller (Netherlands) and Professor Andreas Wollenberg (Germany)
• Navigating new knowledge in prurigo nodularis: restoring hope for sufferers – September 10, 1:00 PM – 2:00 PM CEST (Room: CORAL 6). Chaired by Professor Sonja Ständer (Germany) and Professor Giampiero Girolomoni (Italy), and that includes Professor Doctor Shawn Kwatra (U.S.) and Professor Doctor Bernhard Homey (Germany)

Sensitive pores and skin

• Simplifying delicate pores and skin: can we outline it as a standalone pores and skin situation? – September 7, 1:00 PM – 2:00 PM CEST (Room: CORAL 6). Chaired by Professor Giovanni Pellacani (Italy) and that includes Professor Adam Friedman (U.S.) and Doctor Krzysztof Piotrowski (Switzerland)

Acne

• A novel patient-centered strategy for zits administration – September 8, 1:00 PM – 2:00 PM CEST (Room: CORAL 6). Co-chaired by Professor Alison Layton (UK) and Professor Doctor Jerry Tan (Canada), and that includes Doctor Vincenzo Bettoli (Italy)
• Opportunities for a holistic strategy to zits vulgaris administration – September 9, 9:15 AM -10:00 AM CEST (Room: HUB 2.05). Featuring Professor Brigitte Dreno (France), Professor Gabriella Fabbrocini and Doctor Magda Belmontesi (Italy)
• Acne replace: Recent advances on pores and skin microbiome, pressure co-residence of C. acnes and therapy greatest practices – September 9, 4:00 PM – 4:45 PM CEST (Room: HUB 2.08). Featuring Professor Brigitte Dreno (France) and Professor Tami Lieberman (U.S.)

Rosacea

• Clinical challenges in rosacea: overcoming obstacles on the street to therapy optimization – September 8, 6:00 PM – 7:30 PM CEST (Room: CORAL 6). Featuring Professor Doctor Giuseppe Micali (Italy), Professor Doctor Martin Schaller (Germany) and Professor Doctor Jerry Tan (Canada)

Actinic keratosis / non-melanoma pores and skin most cancers

• An built-in strategy for actinic keratosis and non-melanoma pores and skin most cancers administration – September 8, 2:30 PM – 3:15 PM CEST (Room: HUB 2.03). Chaired by Professor Merete Haedersdal (Denmark) and that includes Professor Claas Ulrich (Germany) and Doctor Magda Belmontesi (Italy)
• Beyond the lesion: Expert suggestions for longitudinal, patient-centered actinic keratosis administration – September 9, 6:00 PM – 7:30 PM CEST (Room: AMBER 3 and 4). Co-chaired by Professor Rolf-Markus Szeimies (Germany) and Professor Colin Morton (UK) and that includes Professor Piergiacomo Calzavara-Pinton (Italy)
• Personalizing Actinic Keratosis Treatment (PAKT): Expert suggestions to help patient-centered administration of actinic keratosis (oral presentation) – September 10, 10:15 AM CEST (Room: BROWN 2, FC05: Free comms in cutaneous oncology and genetics). Featuring Professor Rolf-Markus Szeimies (Germany)

Onychomycosis

• Onychomycosis replace: Quantified penetration profile of topical amorolfine in contaminated human nails – September 8, 9:15 AM – 10:00 AM CEST (Room: HUB 2.01). Featuring Professor Martin Schaller (Germany)

A broad vary of latest scientific knowledge posters has been accepted for EADV this yr and might be offered upon request.

About Galderma

Galderma is the pure-play dermatology class chief, current in roughly 90 international locations. We ship an progressive, science-based portfolio of premium flagship manufacturers and providers that span the total spectrum of the fast-growing dermatology market by way of Injectable Aesthetics, Dermo-Cosmetics and Therapeutic Dermatology. Since our basis in 1981, we’ve devoted our focus and fervour to the human physique’s largest organ – the pores and skin – assembly particular person client and affected person wants with superior outcomes in partnership with healthcare professionals. Because we perceive that the pores and skin we’re in shapes our lives, we’re advancing dermatology for each pores and skin story. Galderma’s portfolio of flagship manufacturers consists of Restylane, Dysport, Azzalure, Alluzience and Sculptra in Injectable Aesthetics; Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac and Loceryl in Therapeutic Dermatology; and Cetaphil and Alastin in Dermo-cosmetics. For extra data: www.galderma.com.

References

1.Williams KA, Roh YS, Brown I, et al. Pathophysiology, analysis, and pharmacological therapy of prurigo nodularis. Expert Rev Clin Pharmakoi.2021;14(1):67-77. doi:10.1080/17512433.2021.1852080

2. Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the hole between immune cells, the nervous system and epithelial tissues. Front Med (Lausanne). 2021;8: 639097. doi:10.3389/fmed.2021.639097

3. Farage, Miranda A. “The Prevalence of Sensitive Skin.” US National Library of Medicine National Institutes of Health, www.ncbi.nlm.nih.gov/pmc/articles/PMC6533878.

View supply model on businesswire.com: https://www.businesswire.com/news/home/20220905005330/en/